NCT02040857View on ClinicalTrials.gov

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2018

Study Completion Date

December 27, 2024

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib

CDK 4/6 inhibitor

DRUG

Aromatase Inhibitor

Endocrine Therapy

Trial Locations (10)

19104

University of Pennsylvania-Abramson Cancer Center, Philadelphia

46202

Indiana University Health Hospital, Indianapolis

94115

University of California, San Francisco, San Francisco

02214

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

01923

MGH/North Shore Cancer Center, Danvers

01757

DF/DWCC at Milford Regional Cancer Center, Milford

02190

South Shore Hospital, Weymouth

03053

Dana-Farber/New Hampshire Oncology-Hematology, Londonderry

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02040857 - Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | Biotech Hunter | Biotech Hunter